Cargando…
The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry
Vesicle-membrane-protein-associated protein A (VAPA) and oxysterol-binding protein (OSBP) regulate intracellular cholesterol homeostasis, which is required for many virus infections. During entry, viruses or virus-containing vesicles can fuse with endosomal membranes to mediate the cytosolic release...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646482/ https://www.ncbi.nlm.nih.gov/pubmed/23601107 http://dx.doi.org/10.1016/j.chom.2013.03.006 |
_version_ | 1782268603069890560 |
---|---|
author | Amini-Bavil-Olyaee, Samad Choi, Youn Jung Lee, Jun Han Shi, Mude Huang, I-Chueh Farzan, Michael Jung, Jae U. |
author_facet | Amini-Bavil-Olyaee, Samad Choi, Youn Jung Lee, Jun Han Shi, Mude Huang, I-Chueh Farzan, Michael Jung, Jae U. |
author_sort | Amini-Bavil-Olyaee, Samad |
collection | PubMed |
description | Vesicle-membrane-protein-associated protein A (VAPA) and oxysterol-binding protein (OSBP) regulate intracellular cholesterol homeostasis, which is required for many virus infections. During entry, viruses or virus-containing vesicles can fuse with endosomal membranes to mediate the cytosolic release of virions, and alterations in endosomal cholesterol can inhibit this invasion step. We show that the antiviral effector protein interferon-inducible transmembrane protein 3 (IFITM3) interacts with VAPA and prevents its association with OSBP, thereby disrupting intracellular cholesterol homeostasis and inhibiting viral entry. By altering VAPA-OSBP function, IFITM3 induces a marked accumulation of cholesterol in multivesicular bodies and late endosomes, which inhibits the fusion of intraluminal virion-containing vesicles with endosomal membranes and thereby blocks virus release into the cytosol. Consequently, ectopic expression or depletion of the VAPA gene profoundly affects IFITM3-mediated inhibition of viral entry. Thus, IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry, further underscoring the importance of cholesterol in virus infection. |
format | Online Article Text |
id | pubmed-3646482 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Elsevier Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-36464822014-04-17 The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry Amini-Bavil-Olyaee, Samad Choi, Youn Jung Lee, Jun Han Shi, Mude Huang, I-Chueh Farzan, Michael Jung, Jae U. Cell Host Microbe Article Vesicle-membrane-protein-associated protein A (VAPA) and oxysterol-binding protein (OSBP) regulate intracellular cholesterol homeostasis, which is required for many virus infections. During entry, viruses or virus-containing vesicles can fuse with endosomal membranes to mediate the cytosolic release of virions, and alterations in endosomal cholesterol can inhibit this invasion step. We show that the antiviral effector protein interferon-inducible transmembrane protein 3 (IFITM3) interacts with VAPA and prevents its association with OSBP, thereby disrupting intracellular cholesterol homeostasis and inhibiting viral entry. By altering VAPA-OSBP function, IFITM3 induces a marked accumulation of cholesterol in multivesicular bodies and late endosomes, which inhibits the fusion of intraluminal virion-containing vesicles with endosomal membranes and thereby blocks virus release into the cytosol. Consequently, ectopic expression or depletion of the VAPA gene profoundly affects IFITM3-mediated inhibition of viral entry. Thus, IFITM3 disrupts intracellular cholesterol homeostasis to block viral entry, further underscoring the importance of cholesterol in virus infection. Elsevier Inc. 2013-04-17 2013-04-17 /pmc/articles/PMC3646482/ /pubmed/23601107 http://dx.doi.org/10.1016/j.chom.2013.03.006 Text en Copyright © 2013 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
spellingShingle | Article Amini-Bavil-Olyaee, Samad Choi, Youn Jung Lee, Jun Han Shi, Mude Huang, I-Chueh Farzan, Michael Jung, Jae U. The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry |
title | The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry |
title_full | The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry |
title_fullStr | The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry |
title_full_unstemmed | The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry |
title_short | The Antiviral Effector IFITM3 Disrupts Intracellular Cholesterol Homeostasis to Block Viral Entry |
title_sort | antiviral effector ifitm3 disrupts intracellular cholesterol homeostasis to block viral entry |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3646482/ https://www.ncbi.nlm.nih.gov/pubmed/23601107 http://dx.doi.org/10.1016/j.chom.2013.03.006 |
work_keys_str_mv | AT aminibavilolyaeesamad theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT choiyounjung theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT leejunhan theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT shimude theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT huangichueh theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT farzanmichael theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT jungjaeu theantiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT aminibavilolyaeesamad antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT choiyounjung antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT leejunhan antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT shimude antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT huangichueh antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT farzanmichael antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry AT jungjaeu antiviraleffectorifitm3disruptsintracellularcholesterolhomeostasistoblockviralentry |